Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings and target prices for Xeris Biopharma and Corcept Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 2 | 4 | 0 | 2.43 |
| Corcept Therapeutics | 1 | 1 | 5 | 1 | 2.75 |
Xeris Biopharma presently has a consensus price target of $13.20, indicating a potential upside of 31.08%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 15.55%. Given Xeris Biopharma’s higher possible upside, research analysts clearly believe Xeris Biopharma is more favorable than Corcept Therapeutics.
Volatility & Risk
Valuation and Earnings
This table compares Xeris Biopharma and Corcept Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $291.85 million | 6.29 | $550,000.00 | ($0.11) | -91.55 |
| Corcept Therapeutics | $761.41 million | 16.98 | $99.65 million | $0.42 | 284.69 |
Corcept Therapeutics has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Xeris Biopharma and Corcept Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | -5.12% | 338.21% | 3.50% |
| Corcept Therapeutics | 6.52% | 8.26% | 6.45% |
Insider and Institutional Ownership
42.7% of Xeris Biopharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 4.3% of Xeris Biopharma shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Corcept Therapeutics beats Xeris Biopharma on 12 of the 15 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
